SSEA-3 pluripotent stem cell isolated from body tissue
Objects of the present invention are to provide a method for directly obtaining pluripotent stem cells from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stem cells that can be isolated from body tissue.
1. A method for enriching for human cells isolated from mesodermal or mesenchymal tissue of a living mammalian body, the method comprising (a) isolating human mesodermal or
human mesenchymal cells that express SSEA-3 from human mesodermal or mesenchymal cells; and (b) collecting the SSEA-3 (+) human cells which comprise SSEA-3(+) human cells which are capable of forming cell clusters, the cell clusters including SSEA-3(+)
human cells which: (i) exhibit low or no telomerase activity; (ii) are capable of differentiating into three germ layers; (iii) exhibit the lack of neoplastic proliferation; (iv) exhibit self-renewal capability; (v) are CD31 (-); (vi) are CD105(+);
and (c) enriching the SSEA-3(+) human cells which exhibits (i) to (vi) above.
2. The method according to claim 1, wherein the human cell further has the following properties: (i) being negative for CD117 and negative for CD146; (ii) being negative for CD117, negative for CD146, negative for NG2, negative for CD34,
negative for vWF, and negative for CD271; (iii) being negative for CD34, negative for CD117, negative for CD146, negative for CD271, negative for NG2, negative for vWF, negative for Sox10, negative for Snail, negative for Slug, negative for Tyrp1, and
negative for Dct; and (iv) having low or no telomerase activity.
3. A method for enriching human cells isolated from mesodermal or mesenchymal tissue of a living mammalian body, the method comprising: (a) exposing a population of human mesodermal or human mesenchymal cells to cellular stress which is dispase
or collagenase incubation; (b) collecting surviving cells which comprises at least 9% of human cells which can form cell clusters, the cell clusters including cells which comprise the following phenotypes: (i) are SSEA-3 (+); (ii) exhibit low or no
telomerase activity; (iii) exhibit a lack of neoplastic proliferation; (iv) exhibit self-renewal capability; (v) exhibit a lack of CD31 expression or CD31 (-); (vi) are CD105(+); and (c) enriching the human cells which comprises phenotypes (i) to
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.